Cost benefit evaluation of routine influenza immunisation in subjects 65-74 years of age

Not Applicable

Completed

• Conditions: Infection and infestations: Influenza; Infections and Infestations; Influenza

• Registration Number: ISRCTN27879030
• Lead Sponsor: Department of Health (UK)

Brief Summary

2003 results in: https://www.ncbi.nlm.nih.gov/pubmed/14499051

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2002-08-31
• Study Start: 2003-04-25
• Last Update Posted: 29 July 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 729

Inclusion Criteria

65-74 year olds

Exclusion Criteria

Aged over 75 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1.1 Hospital admission with or without respiratory illness<br> 1.2 GP consultation for respiratory and non-respiratory disease<br> 1.3 Self- reported patient illness and over the counter medication<br> 1.4 Quality of Life measures at 3, 6, 9 and 12 months post vaccination.<br> 2. To determine the cost effectiveness of the vaccination.<br> 3. To determine whether factors such as age, sex, co-morbidity and social class affects, 3.1 entry into the trial, 3.2 the receipt or otherwise of the influenza vaccination outside the clinical trial, 3.3 cost effectiveness.<br>

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration.